金活医药集团(01110)发布年度业绩 股东应占溢利3809.6万元 同比增加67.52%
金活医药集团(01110)发布截至2023年12月31日止年度的年度业绩，该集团期内取得收益10.79亿元(人民币，下同)，同比减少12.63%;股东应占溢利3809.6万元，同比增加67.52%;每股基本盈利6.44分;拟派发末期股息每股3.38港仙。
公告称，收益增加主要原因为京都念慈菴蜜炼川贝枇杷膏的收益增加所致。该项增加主要原因为疫情防控及对疫情有更好的了解，使市场需求在回顾年度期间相对截至2022年12月31日止年度趋向复苏而有所增加所致。惟部分给东迪欣生产的医疗设备产品，包括红外线测温仪，销售减少所抵销。此类防疫产品于截至2022年12月31日止年度内需求很大。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.